ArticleJournal of inflammation research2026
Mitochondrial Hub Genes in Rheumatoid Arthritis Identified by Machine Learning and Mendelian Randomization with Experimental Validation.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) has complex pathological mechanisms, and mitochondria are critical to its occurrence and development while the specific mechanisms remain unclear. This study aimed to identify key mitochondria-related genes in RA via machine learning, validate them by two-sample Mendelian randomization (MR), and provide novel therapeutic target clues. Methods: RA-associated gene microarray datasets from GEO were curated by R software. Differential expression profiling, LASSO regression, SVM classification and RF modeling were used to screen hub genes and build diagnostic models. GO, KEGG and Metascape analyses clarified their biological roles, and immune infiltration profiling and consensus clustering were performed for immune heterogeneity analysis. MR analysis identified core genes linked to RA susceptibility, followed by drug enrichment and molecular docking. A preliminary RT-qPCR validation was conducted on synovial tissues from a small cohort of 3 RA patients and 3 controls. Results: A total of 1,432 differentially expressed genes (DEGs) were identified, and six mitochondria-related hub genes (UCP2, BCL2A1, FASN, AKR1B10, IFI27, PDK1) were screened by machine learning. The diagnostic model based on these genes had good discriminatory ability. MR analysis confirmed a causal relationship between BCL2A1 and RA, suggesting it as a potential risk factor. Drug enrichment and molecular docking showed these hub genes could bind to candidate drugs, and the exploratory RT-qPCR assay initially validated the bioinformatics findings. Leave-one-out sensitivity analysis confirmed that the RT-qPCR results exhibited good stability. Conclusion: Bioinformatics analysis identified UCP2, BCL2A1, FASN, AKR1B10, IFI27, and PDK1 as potential mitochondria-related diagnostic biomarkers for RA and established a corresponding diagnostic model. MR analysis showed a causal relationship between BCL2A1 and RA, indicating that BCL2A1 serves as a risk factor for the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.